Skip to content
Screener

TransMedics Group, Inc. TMDX Liver Product — Revenue

Other product segments

Heart Product
$30.87M+3.5%
Lung Product
$2.82M-29.6%

Similar metrics at other companies

GigaCloud Technology logo
GCTProduct revenues — Revenue
$290.82M+28.9%
Nine Energy Service logo
NINEProduct revenues — Revenue
$45.59M+23.1%
Ondas, Inc. logo
ONDSProduct Revenue — Revenue
$38.37M+1,090%
RFL
RFLProduct Revenue — Revenue
$89K-63.4%
AMC Robotics Corporation logo
AMCIProduct Revenue — Revenue
$586.62K-68.5%
ROC
ROCProduct Revenue — Revenue
$2.32M-4.7%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.78B-31.3%
Enterprise value$2.73B-26.6%
P/E16.2×-40.3×
P/S4.4×-3.2×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%—

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The source filing: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026.

Filed
May 5, 2026, 4:15 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001193125-26-206453
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Revenue:
Net product revenue$107,972$88,234
Service revenue65,96155,303
Total revenue173,933143,537
Cost of revenue:
Cost of net product revenue24,30816,312
Cost of service revenue48,46438,997
Total cost of revenue72,77255,309

Item 1. Financial Statements (Unaudited)

FAQ

What is TransMedics Group, Inc.'s liver product — revenue?
TransMedics Group, Inc. (TMDX) reported liver product — revenue of $138.98M in Q1 2026.
How has TransMedics Group, Inc.'s liver product — revenue changed year-over-year?
TransMedics Group, Inc.'s liver product — revenue increased by 27.7% year-over-year, from $108.86M to $138.98M.
What is the long-term trend for TransMedics Group, Inc.'s liver product — revenue?
Over 4 years (2021 to 2025), TransMedics Group, Inc.'s liver product — revenue has grown at a 293.8% compound annual growth rate (CAGR), from $1.92M to $460.53M.
What does liver product — revenue mean?
This metric represents the total gross sales generated from the sale of medical devices, disposables, and associated services specifically related to liver organ perfusion and preservation technology. It serves as a key indicator of the commercial adoption and market penetration of the company's organ care systems within the liver transplant clinical community. Growth in this revenue stream reflects the company's ability to displace traditional cold storage methods and expand its footprint in the end-stage liver disease treatment market.

Ask your AI about TransMedics Group, Inc.'s liver product — revenue.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude